Development and automation of an ultra-concentrated bioactive compound containing plasma and platelet proteins for the treatment of anterior segment eye pathologies (BEGIKOREKA)
The primary objective of this project is to develop an ultra-concentrated bioactive compound containing plasma and platelet proteins that increases the bioavailability of proteins and growth factors in the tissues comprising the trabecular meshwork, thereby promoting tissue regeneration.